Proximal DVT · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower proximal DVT compared with placebo (moderate certainty).
1 finding from 1 review
Total PE · people requiring prevention of venous thromboembolism
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
1 finding from 1 review
All causes of death · people requiring prevention of venous thromboembolism
1 finding from 1 review
Total PE · people requiring prevention of venous thromboembolism
Fondaparinux leads to lower total PE compared with placebo (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to higher major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
All causes of death · people requiring prevention of venous thromboembolism
Fondaparinux showed no clear difference in all causes of death compared with placebo (moderate certainty).
1 finding from 1 review
Total VTE · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower total VTE compared with LMWH (moderate certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism
Fondaparinux showed no clear difference in symptomatic VTE compared with LMWH (moderate certainty).
1 finding from 1 review
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in recurrent venous thromboembolism compared with standard therapy (moderate certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in major bleeding during the initial treatment compared with standard therapy (moderate certainty).
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).
1 finding from 1 review
Heparin‐induced thrombocytopenia ‐ not measured · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether fondaparinux plus vitamin K antagonist changes all harmful effects compared with standard therapy (very low certainty).
1 finding from 1 review